Biocon Limited (BIOCON.BO)
- Previous Close
291.70 - Open
292.00 - Bid 309.80 x --
- Ask 310.05 x --
- Day's Range
292.00 - 312.25 - 52 Week Range
217.50 - 312.25 - Volume
1,774,290 - Avg. Volume
472,709 - Market Cap (intraday)
370.469B - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
30.86 - EPS (TTM)
10.03 - Earnings Date May 16, 2024
- Forward Dividend & Yield 1.50 (0.51%)
- Ex-Dividend Date Jul 7, 2023
- 1y Target Est
592.06
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, the company is involved in the integrated discovery, development, and manufacturing services for small and large molecules. It serves customers in approximately 120 countries. The company was incorporated in 1978 and is headquartered in Bengaluru, India.
www.biocon.comRecent News: BIOCON.BO
Performance Overview: BIOCON.BO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIOCON.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIOCON.BO
Valuation Measures
Market Cap
349.11B
Enterprise Value
492.33B
Trailing P/E
29.08
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.49
Price/Book (mrq)
1.84
Enterprise Value/Revenue
3.51
Enterprise Value/EBITDA
11.65
Financial Highlights
Profitability and Income Statement
Profit Margin
8.21%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
146.12B
Net Income Avi to Common (ttm)
12B
Diluted EPS (ttm)
10.03
Balance Sheet and Cash Flow
Total Cash (mrq)
37.86B
Total Debt/Equity (mrq)
75.18%
Levered Free Cash Flow (ttm)
--
Research Analysis: BIOCON.BO
Company Insights: BIOCON.BO
BIOCON.BO does not have Company Insights